Literature DB >> 18579238

Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels.

Dimitris Tousoulis1, Apostolos Drolias, Charalambos Antoniades, Carmen Vasiliadou, Kyriakoula Marinou, George Latsios, Elli Stefanadi, Panagiota Gounari, Gerasimos Siasos, Nikos Papageorgiou, Athanasios Trikas, Christodoulos Stefanadis.   

Abstract

BACKGROUND: Depression has been associated with increased inflammatory process. Although anti-depressive medication has anti-inflammatory effect in major depression, its role in patients with heart failure (HF) is unknown. In the present study we evaluated the impact of antidepressive medication on the expression of proinflammatory cytokines and acute phase response proteins, in patients with HF and major depression.
METHODS: The study population consisted of 250 patients with HF (154 suffering from major depression). Patients with major depression were under selective serotonin reuptake inhibitors (SSRIs, n=120) or tricyclic antidepressants (TCA) and/or serotonin/norepinephrine reuptake inhibitors (SNRIs) (n=34), for at least 6 months.
RESULTS: Levels of TNF-alpha, IL-6, CRP and fibrinogen were not significantly different between HF patients with depression under treatment and those without depression (p=NS for all). However, TNF-alpha and CRP levels were significantly lower in patients receiving TCA/SNRI compared to patients receiving SSRIs or those without depression (p<0.05 for all). Similarly, patients under TCA/SNRI had significantly lower heart rate compared to those treated with SSRIs or those without depression. In multivariate analysis, treatment with SNRI/TCA was an independent predictor for log(TNF-alpha) (beta=0.036(SE:0.016) and log(CRP) (beta=0.099(SE:0.048), p=0.041).
CONCLUSIONS: In the present study we demonstrate for the first time that treatment of patients with HF and major depression with TCAs/SNRIs, is associated with lower levels of TNF-alpha and CRP, suggesting that the type of antidepressive treatment may have a significant effect on the underlying inflammatory process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579238     DOI: 10.1016/j.ijcard.2008.02.013

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

1.  In patients with stable heart failure, soluble TNF-receptor 2 is associated with increased risk for depressive symptoms.

Authors:  Samira Moughrabi; Lorraine S Evangelista; Samer I Habib; Leo Kassabian; Elizabeth Crabb Breen; Adeline Nyamathi; Michael Irwin
Journal:  Biol Res Nurs       Date:  2013-07-30       Impact factor: 2.522

2.  Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey.

Authors:  Mark Hamer; G David Batty; G David Batty; Adrie Seldenrijk; Mika Kivimaki
Journal:  Eur Heart J       Date:  2010-11-30       Impact factor: 29.983

3.  The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review.

Authors:  Rebecca Hedrick; Samuel Korouri; Emile Tadros; Tarneem Darwish; Veronica Cortez; Desiree Triay; Mia Pasini; Linda Olanisa; Nathalie Herrera; Sophia Hanna; Asher Kimchi; Michele Hamilton; Itai Danovitch; Waguih William IsHak
Journal:  Drugs Context       Date:  2020-07-29

Review 4.  The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation.

Authors:  H Kolb; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2009-11-05       Impact factor: 10.122

5.  Relations of depressive symptoms and antidepressant use to body mass index and selected biomarkers for diabetes and cardiovascular disease.

Authors:  Yunsheng Ma; Raji Balasubramanian; Sherry L Pagoto; Kristin L Schneider; James R Hébert; Lawrence S Phillips; Joseph S Goveas; Annie L Culver; Barbara C Olendzki; James Beck; Jordan W Smoller; Deidre M Sepavich; Judith K Ockene; Lisa Uebelacker; Martha Zorn; Simin Liu
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

6.  Anti-depressant medication use and C-reactive protein: results from two population-based studies.

Authors:  Mark Hamer; G D Batty; Michael G Marmot; Archana Singh-Manoux; Mika Kivimäki
Journal:  Brain Behav Immun       Date:  2010-09-21       Impact factor: 7.217

Review 7.  Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.

Authors:  Paula Kopschina Feltes; Janine Doorduin; Hans C Klein; Luis Eduardo Juárez-Orozco; Rudi Ajo Dierckx; Cristina M Moriguchi-Jeckel; Erik Fj de Vries
Journal:  J Psychopharmacol       Date:  2017-06-27       Impact factor: 4.153

8.  Brief report: Characteristics of antidepressant use in patients with heart failure.

Authors:  Paul J Mills; Joel E Dimsdale; Suzi Hong; Geoffrey Van Den Brande; Laura Redwine; Barry H Greenberg; Thomas Rutledge
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

10.  Increased C-reactive protein concentration and suicidal behavior in people with psychiatric disorders: A systematic review and meta-analysis.

Authors:  Alessandro Miola; Veronica Dal Porto; Tal Tadmor; Giovanni Croatto; Paolo Scocco; Mirko Manchia; Andre F Carvalho; Michael Maes; Eduard Vieta; Fabio Sambataro; Marco Solmi
Journal:  Acta Psychiatr Scand       Date:  2021-08-25       Impact factor: 7.734

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.